Group II Phospholipases A2
"Group II Phospholipases A2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subcategory of secreted phospholipases A2 that includes enzymes isolated from a variety of sources. The creation of this group is based upon similarities in the structural determinants of the enzymes including a negatively charged carboxy-terminal segment.
| Descriptor ID |
D054501
|
| MeSH Number(s) |
D08.811.277.352.100.680.750.937.750.550
|
| Concept/Terms |
Group II Phospholipases A2- Group II Phospholipases A2
- PLA2-II
- PLA2 II
- Phospholipases A2, Group II
- PLA(2)-II
- Group II Secretory Phospholipase A2
- Phospholipase A2-II
- Phospholipase A2 II
Group IIE phospholipase A2- Group IIE phospholipase A2
- sPLA(2)-IIE
- Phospholipase A2, Group IIE
- Group IIE Secretory Phospholipase A2
- Secretory Phospholipase A2 Type IIE
Group IIA Phospholipase A2- Group IIA Phospholipase A2
- Nonpancreatic Secretory Group II PLA2
- Synovial Fluid Secretory PLA2
- Phospholipase A2, Group IIA
- Synovial Fluid Secretory Phospholipase A2
- Group IIA Secretory Phospholipase A2
- Nonpancreatic Secretory Phospholipase A2
|
Below are MeSH descriptors whose meaning is more general than "Group II Phospholipases A2".
Below are MeSH descriptors whose meaning is more specific than "Group II Phospholipases A2".
This graph shows the total number of publications written about "Group II Phospholipases A2" by people in this website by year, and whether "Group II Phospholipases A2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Group II Phospholipases A2" by people in Profiles.
-
Gene expression signature analysis identifies vorinostat as a candidate therapy for gastric cancer. PLoS One. 2011; 6(9):e24662.
-
HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol. 2009 Feb; 29(2):261-7.
-
Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant. Arterioscler Thromb Vasc Biol. 2006 Jul; 26(7):1421-2.
-
Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit. 2006 Jan; 12(1):RA5-16.
-
Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Res. 2004 Oct 01; 64(19):6934-40.
-
Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2004 Apr; 24(4):762-7.
-
Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood. 2003 Oct 15; 102(8):2901-9.
-
Interaction of low molecular weight group IIA phospholipase A2 with apoptotic human T cells: role of heparan sulfate proteoglycans. FASEB J. 2003 Jun; 17(9):1068-80.
-
Efficacy and safety of LY315920Na/S-5920, a selective inhibitor of 14-kDa group IIA secretory phospholipase A2, in patients with suspected sepsis and organ failure. Crit Care Med. 2003 Mar; 31(3):718-28.
-
Macrophage-expressed group IIA secretory phospholipase A2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2003 Feb 01; 23(2):263-8.